- Home
- EMBC
EMBC
Embecta Corp.
as 11-15-2024 4:00pm EST
Embecta Corp is a medical technology company. The company develops innovative technology, services, and solutions that help advance both clinical therapy for patients and clinical processes for healthcare providers. Its products include BD Pyxis, PureWick, Phasix among others.
| Founded: | 1924 | Country: | United States |
| Employees: | N/A | City: | WILMINGTON |
| Market Cap: | 753.0M | IPO Year: | N/A |
| Target Price: | $12.00 | AVG Volume (30 days): | 247.0K |
| Analyst Decision: | Sell | Number of Analysts: | 1 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 1.20 | EPS Growth: | 45.34 |
| 52 Week Low/High: | $9.93 - $19.79 | Next Earning Date: | 11-26-2024 |
| Revenue: | $1,118,900,000 | Revenue Growth: | 0.48% |
| Revenue Growth (this year): | 1.45% | Revenue Growth (next year): | 0.53% |
Latest Embecta Corp. News
EMBC Breaking Stock News: Dive into EMBC Ticker-Specific Updates for Smart Investing
Argus Research
4 days ago
EMBC: What does Argus have to say about EMBC?
GlobeNewswire
5 days ago
UPDATE - embecta to Report Fiscal Fourth Quarter and Full Year 2024 Financial Results
GlobeNewswire
5 days ago
embecta to Report Fiscal Fourth Quarter and Full Year 2024 Financial Results
GlobeNewswire
10 days ago
embecta Celebrates National Diabetes Awareness Month by Ringing Nasdaq Closing Bell
Argus Research
11 days ago
EMBC: What does Argus have to say about EMBC?
Argus Research
a month ago
EMBC: What does Argus have to say about EMBC?
Zacks
2 months ago
Embecta Stock Gains on FDA Clearance for Type 2 Diabetes Insulin Pump
MT Newswires
2 months ago
Sector Update: Health Care Stocks Retreat in Afternoon Trading
Compare EMBC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "EMBC Embecta Corp. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.